Natco Doubles Down On US With Ambitious ANDA Plan

One of India’s leading generic players, Natco Pharma, aims to file at least 10 ANDAs in the US in the next two years to expand its footprint in this key market as more medicines fall off the patent cliff, and analysts say the company - which is also considering new therapeutic areas - could be on the “verge of a breakout” in its US business.